Phenylephrine per se or Combined with Pregabalin Ameliorates Mononeuropathic Pain in Rats

Abbood, Sarah Kadhim and Gomaa, Nariman Essmat Mohamed Abdeltawab and Boldizsár Jr, Imre and Kirchlechner-Farkas, Judit Mária and Kovácsházi, Csenger and Chalabiani, Yashar and Király, Kornél P and Miklya, Ildikó and Giricz, Zoltán and Hársing, László Gábor and Vizi, E. Szilveszter and Al-Khrasani, Mahmoud (2026) Phenylephrine per se or Combined with Pregabalin Ameliorates Mononeuropathic Pain in Rats. PHARMACEUTICS, 18 (3). No. 334. ISSN 1999-4923

Preview

Text PhenylephrineperseorCombinedwithPregabalinAmelioratesMononeuropathicPaininRats.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Background/Objectives: Neuropathic pain (NP) affects approximately 6.9–10% of the population and is inadequately managed by the current therapies, as reflected by a high number needed to treat (NNT). These data highlight the socio-economic burden of NP on healthcare. Thus, the repurposing of existing medications and new drug combinations to enhance therapeutic efficacy are required. Methods/Results: Here, we show that intrathecal phenylephrine (PE) in a dose of 3, 10, or 30 nmol/rat acutely alleviates tactile allodynia in rats with mononeuropathic pain evoked by partial sciatic nerve ligation. Prazosin and idazoxan, which are considered as selective α1- and α2-adrenoreceptor antagonists, respectively, reversed the antiallodynic effects of PE. In ex vivo experiments, PE induced a significant cytosolic [3H]-noradrenaline release from mouse spinal tissue. In addition, in the mouse vas deferens, PE produced smooth muscle contraction in prazosin and idazoxan sensitive manner. As a novelty, in another set of experiments, oral PE (5 mg/kg) and pregabalin (PGB, 25 mg/kg) combination, but not the individual drug treatments, acutely alleviated allodynia in rats with mononeuropathy. In addition, the antiallodynic action of the combination was further enhanced upon chronic treatment. Under isoflurane anesthesia, this combination was devoid of cardiovascular side effects attributed to systolic and diastolic blood pressure, mean arterial pressure, or heart rate. PGB induced motor dysfunction was not altered upon the combination with PE. Conclusions: These data suggest that PE in combination with PGB shows promise in preclinical settings; however, the necessity for further studies is paramount to detail the pharmacokinetic interactions involved.

Actions (login required)

Edit Item